Abstract:Small-molecule ruthenium (Ru) complexes exhibit limitations in terms of nonspecific delivery, rapid metabolism, and low tumor accumulation. Their delivery can be improved through physical encapsulation into nanocarriers via hydrophobic forces, metallophilic interactions, or pi-pi stacking interactions. However, delivering Ru complexes for efficient therapy is substantially hindered by potential leakage of drugs, low drug-loading capacity, or batch-to-batch variations. Moreover, current metalloprodrug-based self-delivery systems necessitate supramolecular interactions, which are unsuitable for Ru complexes because of their octahedral structures. Herein, two self-assembled molecular Ru drugs, Ru-3XOEG and Ru-PEG, are reported. Ru-3XOEG involves a three-arm dendritic oligo(ethylene glycol) (OEG), while Ru-PEG involves a linear poly(ethylene glycol) (PEG) chain. Furthermore, these drugs contain an anticancer Ru moiety and a planar pyrene moiety to render hydrophobic forces and pi-pi stacking supramolecular interactions. Ru-3XOEG self-assembles into large compound micelles. Ru-PEG self-assembles into vesicles. These Ru-containing self-delivered systems exhibit well-defined structures, high Ru loading contents, and long circulation in blood without external nanocarriers. Red light irradiation induces the release of Ru-H2O anticancer agents and the generation of 1O2 to inhibit tumor growth. The presented design of self-assembled molecular Ru complexes opens avenues for the concept of self-delivered metalloprodrugs. Two Ru metalloprodrugs, Ru-3XOEG and Ru-PEG, respectively are designed for enhanced phototherapy. Ru-3XOEG with dendritic ethylene glycol (EG) self-assembles into large compound micelles, while Ru-PEG with linear EG self-assembles into vesicles. The self-delivered Ru-3XOEG and Ru-PEG circulate in the bloodstream and accumulate at tumor sites. Red-light irradiation induces Ru-H2O release and 1O2 generation, inhibiting tumor growth.image

An Amphiphilic Ruthenium Polymetallodrug for Combined Photodynamic Therapy and Photochemotherapy in Vivo

Drug Therapy: an Amphiphilic Ruthenium Polymetallodrug for Combined Photodynamic Therapy and Photochemotherapy in Vivo (adv. Mater. 6/2017)

Photoresponsive ruthenium-containing polymers: potential polymeric metallodrugs for anticancer phototherapy.

Phototherapy: Ruthenium‐Containing Block Copolymer Assemblies: Red‐Light‐Responsive Metallopolymers with Tunable Nanostructures for Enhanced Cellular Uptake and Anticancer Phototherapy (adv. Healthcare Mater. 4/2016)

Biodegradable Ru-Containing Polycarbonate Micelles for Photoinduced Anticancer Multitherapeutic Agent Delivery and Phototherapy Enhancement

Red‐Light‐Controlled Release of Drug–Ru Complex Conjugates from Metallopolymer Micelles for Phototherapy in Hypoxic Tumor Environments

Ruthenium‐Containing Block Copolymer Assemblies: Red‐Light‐Responsive Metallopolymers with Tunable Nanostructures for Enhanced Cellular Uptake and Anticancer Phototherapy

Supramolecular Metallopolymer for Hypoxia-Activated Ruthenium Complexes Delivery and Smart Chemo-Photodynamic Therapy

Photoresponsive Ru Metalloprodrug Assemblies: Red‐Light‐Controlled Self‐Delivery Systems for Enhanced Anticancer Phototherapy

A Tailored Multifunctional Anticancer Nanodelivery System for Ruthenium‐Based Photosensitizers: Tumor Microenvironment Adaption and Remodeling

Amphiphilic Metallodrug Assemblies with Red-Light-Enhanced Cellular Internalization and Tumor Penetration for Anticancer Phototherapy

Fighting Against Drug-Resistant Tumors Using A Dual-Responsive Pt(Iv)/Ru(Ii) Bimetallic Polymer

Biodegradable Ruthenium‐Rhenium Complexes Containing Nanoamplifiers: Triggering ROS‐Induced CO Release for Synergistic Cancer Treatment

Nanostructured polymer assemblies stabilize photoactivatable anticancer ruthenium complexes under physiological conditions.

Sonoinduced Tumor Therapy and Metastasis Inhibition by a Ruthenium Complex with Dual Action: Superoxide Anion Sensitization and Ligand Fracture

CD44-Targeted Photoactivatable Polymeric Nanosystem with On-Demand Drug Release as a "Photoactivatable Bomb" for Combined Photodynamic Therapy-Chemotherapy of Cancer

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Ruthenium Complex-Modified Carbon Nanodots For Lysosome-Targeted One- And Two-Photon Imaging And Photodynamic Therapy

An Estrogen Receptor Targeted Ruthenium Complex As a Two-Photon Photodynamic Therapy Agent for Breast Cancer Cells

A Liposome Encapsulated Ruthenium Polypyridine Complex As a Theranostic Platform for Triple-Negative Breast Cancer.

Ruthenium(II) Polypyridyl Complexes As Mitochondria-Targeted Two-Photon Photodynamic Anticancer Agents